Telix Pharmaceuticals (ASX:TLX) completed the acquisition of US-based biotechnology company ImaginAb for an upfront consideration of $45 million, according to a Friday filing with the Australian bourse.
The company paid $10 million in cash and $31 million in equity through the issue of about 2.1 million shares, with a deferred payment of up to $4 million in equity at the end of a 15-month indemnity period, the filing said.
The company will pay up to $185 million upon achieving key development and commercial milestones, per the filing.
Shares rose 1% in morning trade Friday and earlier reached an all-time high.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.